Inhibikase Therapeutics, Inc. - Common Stock (IKT)

Inhibikase Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly those related to Parkinson's disease

The company aims to address the underlying mechanisms of these conditions by harnessing its proprietary drug discovery platform to identify and develop compounds that can improve patient outcomes. Their research is centered around the modulation of key biological pathways implicated in neurodegeneration, with the goal of offering new treatment options that can enhance the quality of life for individuals affected by these debilitating disorders.